This is what analysts have to say about ImmunoGen, Inc. (NASDAQ:IMGN) after last week.

April 16, 2018 - By Stephen Andrade

ImmunoGen, Inc. (NASDAQ:IMGN) LogoInvestors sentiment increased to 1.38 in 2017 Q4. Its up 0.22, from 1.16 in 2017Q3. It increased, as 26 investors sold ImmunoGen, Inc. shares while 39 reduced holdings. 37 funds opened positions while 53 raised stakes. 101.53 million shares or 15.77% more from 87.70 million shares in 2017Q3 were reported.
Amalgamated Savings Bank reported 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Ngam Advsr Lp, a Massachusetts-based fund reported 280,861 shares. Dynamic Advsrs Solutions Llc invested in 0.05% or 23,438 shares. 11.07M were reported by Clearbridge Invests Ltd Liability Co. Cubist Systematic Strategies Lc invested in 0.02% or 59,225 shares. Aqr Capital Ltd Liability Co accumulated 394,957 shares or 0% of the stock. 132 were reported by Sandy Spring Commercial Bank. Franklin has 0.01% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 3.01M shares. Whittier Tru Co accumulated 0% or 5,300 shares. Credit Suisse Ag reported 127,793 shares. Bnp Paribas Arbitrage accumulated 20,506 shares. Sphera Funds Management owns 500,000 shares. Contravisory Invest holds 0% or 73 shares in its portfolio. Manufacturers Life Insur The accumulated 77,143 shares or 0% of the stock. Da Davidson & holds 0.01% or 93,349 shares in its portfolio.

Since February 13, 2018, it had 0 insider purchases, and 12 insider sales for $3.27 million activity. Shares for $292,000 were sold by JUNIUS DANIEL M. $736,084 worth of stock was sold by Enyedy Mark J on Wednesday, February 21. Ryll Thomas sold 11,876 shares worth $129,211. $115,300 worth of ImmunoGen, Inc. (NASDAQ:IMGN) was sold by Johnston David Brannon on Thursday, March 15. Berkenblit Anna sold $188,540 worth of stock or 17,329 shares. Shares for $375,208 were sold by Gregory Richard J..

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Among 5 analysts covering ImmunoGen (NASDAQ:IMGN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. ImmunoGen had 8 analyst reports since November 3, 2017 according to SRatingsIntel. The company was maintained on Thursday, February 1 by Canaccord Genuity. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) earned “Buy” rating by Canaccord Genuity on Monday, March 26. The firm has “Buy” rating by Jefferies given on Monday, March 26. The rating was maintained by Canaccord Genuity on Friday, November 3 with “Buy”. As per Friday, November 3, the company rating was maintained by Jefferies. RBC Capital Markets initiated ImmunoGen, Inc. (NASDAQ:IMGN) on Thursday, February 8 with “Buy” rating. The stock has “Hold” rating by Cantor Fitzgerald on Friday, April 6. Below is a list of ImmunoGen, Inc. (NASDAQ:IMGN) latest ratings and price target changes.

06/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $5.0000 Maintain
26/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $20.0000 Maintain
26/03/2018 Broker: Jefferies Rating: Buy New Target: $15.0000 Maintain
08/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Initiate
01/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0 Maintain
31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $11.0 Maintain
03/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $10.0 Maintain

The stock increased 1.78% or $0.18 during the last trading session, reaching $10.28. About 802,324 shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 195.97% since April 16, 2017 and is uptrending. It has outperformed by 184.42% the S&P500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.37 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.